PharmiWeb.com - Global Pharma News & Resources
04-May-2021

[2021] Global Inhaled Antibiotics Market Potential Prospects during the Forecast Period 2020 – 2027 | Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals

SEATTLE, May 04, 2021, (PHARMIWEB) —

Global Inhaled Antibiotics Market, by Product Type (Aerosol, Dry Powder Formulation, and Spray), by Application (Pneumonia, Asthma, Bronchitis, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,160.69 million in 2020 and is projected to register a CAGR  around 6.3% during the forecast period (2020–2027), as highlighted in a new report published by Coherent Market Insights.

Major players are focusing on inorganic growth initiatives such as acquisition and partnership due to broaden their product line and position in the global inhaled antibiotics Market.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/3980

For instance, in April 2020, Savara Inc., a clinical-stage pharmaceutical company, entered into an exclusive license and collaboration agreement with Grifols S.A., a Spanish multinational pharmaceutical and chemical manufacturer company, to develop and commercialize Apulmiq (inhaled liposomal ciprofloxacin), also known as Linhaliq, in Europe. Apulmiq is a late-stage investigational inhaled antibiotic in phase 3 development for non-cystic fibrosis bronchiectasis (NCFB) treatment.

Furthermore, in February 2020, Grifols S.A., a Spanish multinational pharmaceutical and chemical manufacturer company, acquired Aradigm Corporation, a specialty pharmaceutical company. As a result of this acquisition, Grifols S.A. purchased Lipoquin, Free Ciprofloxacin, Apulmiq, and other antibiotic portfolio of Aradigm Corporation.

Moreover, increased research and development efforts for the development of new products, is expected to propel the global inhaled antibiotics market growth during the forecast period. For instance, in September 2019, Portugal-based Hovione Technology, a company developing inhalation devices, entered into a collaboration agreement with the Kiel University’s Institute of Pharmacy in Germany. As a result of this agreement, the institution utilized Hovione’s portfolio of large dose dry-powder inhalers (DPIs) to conduct research on advanced formulation approaches for high-dose inhalation applications.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3980

Global Inhaled Antibiotics Market – Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic is posing significant threats to the major players in the global inhaled antibiotics market on a number of fronts. Supply of raw materials such as APIs for antibiotics production is a major concern due to irregularities in transportation facility, which would have an effect on the global distribution channel. Furthermore, owing to a growing patient population suffering from respiratory conditions such as asthma, COPD, and the novel COVID-19, patients are facing differing levels of demand. Moreover, COVID-19 is even particularly dangerous for people who have a medical history of diabetes, serious asthma, or heart disease. There is some fear that COVID 19 could cause extreme asthmatic patients to have a worse outcome, although there is no definitive evidence to back this up. However, the global effects of the coronavirus (Covid-19) pandemic is likely to limit the global inhaled antibiotics market’s development in the near future.

Rising government initiatives for the production of new products, is expected to drive the global inhaled antibiotics market growth during the forecast period. For instance, in July 2018, the U.S. Food and Drug Administration held a public workshop on development of inhaled antibacterial drugs for cystic fibrosis and non-cystic fibrosis bronchiectasis. The aim of the public workshop was to talk about the problems of designing clinical trials for inhaled antibacterial drugs to treat cystic fibrosis (CF) and non-CF bronchiectasis.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/3980

Detailed Segmentation:

Global Inhaled Antibiotics Market, By Product Type:

    • Aerosol
    • Dry Powder Formulation
    • Spray

Global Inhaled Antibiotics Market, By Application:

    • Pneumonia
    • Asthma
    • Bronchitis
    • Others

Global Inhaled Antibiotics Market, By Distribution Channel:

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/inhaled-antibiotics-market-3248

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. Shah
Coherent Market Insights,
1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 04-May-2021